Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 30Withdrawn 4Recruiting 3Active not recruiting 3Unknown 2Terminated 1No longer available 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Prostate Adenocarcinoma 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Carcinoma, Renal Cell 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

enzalutamide 33Abiraterone Acetate 28apalutamide 25Radiotherapy 25Prednisone 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 21Radiosurgery 19darolutamide 18Docetaxel 17acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Gonadotropin-Releasing Hormone 14gallium 68 PSMA-11 12Specimen Handling 12Goserelin 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Radiation 11bicalutamide 10abiraterone 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Standard of Care 8Nivolumab 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × radium Ra 223 dichloride × Clear all
NCT03344211 2026-06-03

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

University of Southern California

Phase 2 Active not recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
132 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

University of California, San Francisco

Phase 2 Active not recruiting
2 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡